107 related articles for article (PubMed ID: 10680732)
41. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis.
Martin NE; Chen MH; Catalona WJ; Loeb S; Roehl KA; D'Amico AV
Cancer; 2008 Aug; 113(4):717-22. PubMed ID: 18615505
[TBL] [Abstract][Full Text] [Related]
42. Prostate-specific antigen screening and mortality from prostate cancer.
Marcella SW; Rhoads GG; Carson JL; Merlino F; Wilcox H
J Gen Intern Med; 2008 Mar; 23(3):248-53. PubMed ID: 18172740
[TBL] [Abstract][Full Text] [Related]
43. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies.
Etzioni R; Cha R; Cowen ME
J Urol; 1999 Sep; 162(3 Pt 1):741-8. PubMed ID: 10458357
[TBL] [Abstract][Full Text] [Related]
44. Mass screening of prostate cancer in Changchun City of China.
Li X; Tsuji I; Kuwahara M; Zhang H; Wang H; Zhang L; Ji G; Zhao X
Int Urol Nephrol; 2004; 36(4):541-8. PubMed ID: 15787333
[TBL] [Abstract][Full Text] [Related]
45. Usefulness of prostate-specific antigen velocity in screening for prostate cancer.
Ito K; Yamamoto T; Ohi M; Kubota Y; Fukabori Y; Kurokawa K; Suzuki K; Yamanaka H
Int J Urol; 2002 Jun; 9(6):316-21. PubMed ID: 12110095
[TBL] [Abstract][Full Text] [Related]
46. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
47. Prostate cancer screening: issues and controversies.
O'Shaughnessy M; Konety B; Warlick C
Minn Med; 2010 Aug; 93(8):39-44. PubMed ID: 20862878
[TBL] [Abstract][Full Text] [Related]
48. Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening.
D'Amico AV; Whittington R; Malkowicz SB; Renshaw AA; Tomaszewski JE; Bentley C; Schultz D; Rocha S; Wein A; Richie JP
Urology; 2001 Sep; 58(3):406-10. PubMed ID: 11549489
[TBL] [Abstract][Full Text] [Related]
49. Impact of screening on prostate cancer rates and trends.
Mettlin C
Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
[TBL] [Abstract][Full Text] [Related]
50. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates.
Feuer EJ; Mariotto A; Merrill R
Cancer; 2002 Aug; 95(4):870-80. PubMed ID: 12209732
[TBL] [Abstract][Full Text] [Related]
51. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths.
Neppl-Huber C; Zappa M; Coebergh JW; Rapiti E; Rachtan J; Holleczek B; Rosso S; Aareleid T; Brenner H; Gondos A;
Ann Oncol; 2012 May; 23(5):1325-1334. PubMed ID: 21965474
[TBL] [Abstract][Full Text] [Related]
52. Does testing for prostate-specific antigen contribute to declining prostate cancer mortality? Estimating the broader economic influences on aggregate prostate cancer mortality rates.
Di Matteo L; Di Matteo R
Eur J Health Econ; 2005 Dec; 6(4):298-308. PubMed ID: 16180027
[TBL] [Abstract][Full Text] [Related]
53. Prostate cancer--testing, incidence, surgery and mortality.
Gibbons L; Waters C
Health Rep; 2003 May; 14(3):9-20. PubMed ID: 12816012
[TBL] [Abstract][Full Text] [Related]
54. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
55. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.
Jacobsen SJ; Katusic SK; Bergstralh EJ; Oesterling JE; Ohrt D; Klee GG; Chute CG; Lieber MM
JAMA; 1995 Nov; 274(18):1445-9. PubMed ID: 7474190
[TBL] [Abstract][Full Text] [Related]
56. PSA screening and prostate cancer mortality.
Perron L; Moore L; Bairati I; Bernard PM; Meyer F
CMAJ; 2002 Mar; 166(5):586-91. PubMed ID: 11898936
[TBL] [Abstract][Full Text] [Related]
57. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
58. Using age-referenced prostate-specific antigen percentile to predict survival outcomes in screened Taiwanese men.
Chen CH; Yao HH; Huang SW; Chuang CK; Hsu HS; Wang CJ; Pu YS
Int J Cancer; 2013 Apr; 132(8):1927-32. PubMed ID: 22987331
[TBL] [Abstract][Full Text] [Related]
59. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
60. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]